A Phase 4 interventional study of Aprepitant and Aprepitant Placebo in Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2018-09-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing aprepitant in Nausea — 1 open to participants now, 1 under way, none of them phase 3. Aprepitant · Nausea.
Among the 40 studies testing aprepitant in Nausea, this one has the largest enrollment, is one of 2 that started in 2012, is one of 9 in phase 4, and was the 32nd registered.
644 studies on the registry are indexed under Nausea; 85 are open to participants now.
Browse Nausea studies →1 of the 40 studies testing aprepitant in Nausea is open now, in 1 country. Recruiting first, the newest first:
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+
By country, each count listing its studies:
Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 51 Nausea studies recruiting now, 21 (41%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 494 is above the median of 96 across 544 interventional studies indexed under Nausea.
Median enrollment 49 across the 40 interventional studies. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
11 studies in Nausea by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 11 finished, 4 (36%) have results posted.
Among the 11 studies in Nausea by Merck & Co., Inc, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2012, is one of 5 in phase 4, and was the 10th registered.
Merck & Co., Inc’s Nausea studies by the year they started, since 2002.
1 of the studies testing aprepitant in Nausea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371728Sir Mortimer B. Davis - Jewish General HospitalEffect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing aprepitant in Nausea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 11 in Nausea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an efficacy and safety study to compare aprepitant with ondansetron for the prevention of nausea and vomiting in the first cycle of moderately emetogenic chemotherapy (MEC) in participants with solid tumors. MECs include a number of commonly used cancer chemotherapeutic drugs including: oxaliplatin-based, irinotecan-based, and carboplatin-based regimens.
The primary hypothesis of this study is that the Aprepitant Regimen is superior to the Control (ondansetron) Regimen with respect to the percentage of participants with No Vomiting Overall (in the 120 hours following initiation of MEC) in participants with solid tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive one aprepitant 125 mg capsule by mouth (PO) once daily (QD) on Day 1 and one aprepitant 80 mg capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg intravenously (IV) QD and dexamethasone 12 mg PO on Day 1 and placebo for ondansetron 8 mg PO twice daily (BID) on Days 2 and 3.
Drug: Aprepitant · Drug: Ondansetron · Drug: Dexamethasone · Drug: Ondansetron Placebo · Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
Participants receive one placebo capsule PO QD on Day 1 and one placebo capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg IV QD and dexamethasone 20 mg PO on Day 1 and ondansetron 8 mg PO BID on Days 2 and 3.
Drug: Aprepitant Placebo · Drug: Ondansetron · Drug: Dexamethasone · Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
Also known as: MK-0869, EMEND® PO
Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
Also known as: ZOFRAN®
Dexamethasone (20 mg or 12 mg, PO) on Day 1
Also known as: dexamethasone sodium phosphate, dexamethasone acetate, Decadron, Dexasone, Diodex, Hexadrol, Maxidex
Ondansetron Placebo (PO, BID) on Days 2 and 3
Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
The Percentage of Participants With No Vomiting - Overall Stage
A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). No vomiting during the Overall Stage was defined as no episodes of emesis during the 120 hours (Days 1-5) after initiation of moderately emetogenic chemotherapy (MEC).
Time frame: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages
A Complete Response was defined as no vomiting or dry heaves and no use of a rescue therapy. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.
Time frame: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
Number of Emetic Events - Overall Stage
The number of emetic events that occurred during the Overall Stage (0 to 120 hours after initiation of MEC) are presented.
Time frame: Hour 0 on Day 1 to Day 5 (approximately 120 hours)
Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage
Nausea was to be assessed using a 100-mm horizontal visual analogue scale (VAS) located in the participant diary labeled: "How much nausea have you had over the last 24 hours?" The left end of the scale (0 mm) was labeled "no nausea," and the right end of the scale (100 mm) is labeled "nausea as bad as it could be." In this study, No Significant Nausea was defined as a VAS nausea rating \<25 mm.
Time frame: Days 1 to Day 5
Percentage of Participants With No Impact on Daily Life - Overall Stage
The Functional Living Index-Emesis questionnaire (FLIE) is a validated, participant-reported instrument to measure the impact of chemotherapy-induced nausea and vomiting on daily life. There are 9 nausea-related items and 9 vomiting-related items, each on a 7-point scale. For the purposes of this study, "No Impact" on daily life was defined as an average item score of \>6 on the 7-point scale; a total score \>108 indicates no impact on daily life. Overall Stage=0 to 120 hours after initiation of MEC.
Time frame: Day 6
Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages
The percentage of participants who used no rescue therapy after initiation of MEC is presented for the Overall, Acute and Delayed Stages. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.
Time frame: Day 1 to Day 5
Percentage of Participants With One or More Clinical Adverse Event
An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition, which is temporally associated with the use of the study drug, is also an adverse event. Nausea and vomiting experienced during Days 1-6 were not counted as adverse events unless they were reported as a serious adverse event.
Time frame: Day 1 through Day 29 (Up to 28 days after first dose of study drug)
Percentage of Participants With No Vomiting - Acute and Delayed Stages
A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.
Time frame: Day 1, Day 2 to Day 5
| Milestone | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Started | 244 | 250 |
| Treated | 242 | 248 |
| Completed | 232 | 239 |
| Not completed | 12 | 11 |
| Withdrew: Not treated | 2 | 2 |
| Withdrew: Lost to follow-up | 4 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Did not meet eligibility criteria | 1 | 4 |
A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). No vomiting during the Overall Stage was defined as no episodes of emesis during the 120 hours (Days 1-5) after initiation of moderately emetogenic chemotherapy (MEC).
| Percentage of Participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| The Percentage of Participants With No Vomiting - Overall Stage | 77.2 | 72.0 |
A Complete Response was defined as no vomiting or dry heaves and no use of a rescue therapy. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.
| Percentage of Participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Overall Stage | 73.4 | 70.4 |
| Acute Stage | 95.8 | 97.9 |
| Delayed Stage | 74.3 | 71.2 |
The number of emetic events that occurred during the Overall Stage (0 to 120 hours after initiation of MEC) are presented.
| Number of Emetic Events | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Number of Emetic Events - Overall Stage | 54 | 68 |
Nausea was to be assessed using a 100-mm horizontal visual analogue scale (VAS) located in the participant diary labeled: "How much nausea have you had over the last 24 hours?" The left end of the scale (0 mm) was labeled "no nausea," and the right end of the scale (100 mm) is labeled "nausea as bad as it could be." In this study, No Significant Nausea was defined as a VAS nausea rating \<25 mm.
| Percentage of Participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage | 76.4 | 72.4 |
The Functional Living Index-Emesis questionnaire (FLIE) is a validated, participant-reported instrument to measure the impact of chemotherapy-induced nausea and vomiting on daily life. There are 9 nausea-related items and 9 vomiting-related items, each on a 7-point scale. For the purposes of this study, "No Impact" on daily life was defined as an average item score of \>6 on the 7-point scale; a total score \>108 indicates no impact on daily life. Overall Stage=0 to 120 hours after initiation of MEC.
| Percentage of Participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Percentage of Participants With No Impact on Daily Life - Overall Stage | 76.8 | 73.8 |
The percentage of participants who used no rescue therapy after initiation of MEC is presented for the Overall, Acute and Delayed Stages. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.
| Percentage of Participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Overall Stage | 84.8 | 87.7 |
| Acute Stage | 98.7 | 99.2 |
| Delayed Stage | 84.8 | 88.5 |
An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition, which is temporally associated with the use of the study drug, is also an adverse event. Nausea and vomiting experienced during Days 1-6 were not counted as adverse events unless they were reported as a serious adverse event.
| Percentage of Participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Percentage of Participants With One or More Clinical Adverse Event | 56.2 | 53.2 |
A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.
| Percentage of Participants | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Acute Stage | 95.8 | 98.8 |
| Delayed Stage | 78.5 | 72.4 |
Collected over Up to 28 days after first dose of study drug (Up to 29 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aprepitant Regimen | — | 25/242 (10.3%) | 87/242 (36%) |
| Control Regimen | — | 16/248 (6.5%) | 96/248 (38.7%) |
| Event | Aprepitant Regimen | Control Regimen |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 4/242 | 5/248 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/242 | 2/248 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/242 | 1/248 |
| AstheniaGeneral disorders | 3/242 | 1/248 |
| PyrexiaGeneral disorders | 3/242 | 3/248 |
| HyponatraemiaMetabolism and nutrition disorders | 2/242 | 0/248 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/242 | 1/248 |
| Abdominal painGastrointestinal disorders | 2/242 | 1/248 |
| DiarrhoeaGastrointestinal disorders | 2/242 | 1/248 |
| IleusGastrointestinal disorders | 2/242 | 0/248 |
| Event | Aprepitant Regimen | Control Regimen |
|---|---|---|
| Neutrophil count decreasedInvestigations | 22/242 | 21/248 |
| ConstipationGastrointestinal disorders | 10/242 | 22/248 |
| NauseaGastrointestinal disorders | 20/242 | 20/248 |
| MyalgiaMusculoskeletal and connective tissue disorders | 11/242 | 18/248 |
| DiarrhoeaGastrointestinal disorders | 14/242 | 17/248 |
| AlopeciaSkin and subcutaneous tissue disorders | 9/242 | 17/248 |
| HiccupsRespiratory, thoracic and mediastinal disorders | 15/242 | 6/248 |
| Decreased appetiteMetabolism and nutrition disorders | 14/242 | 15/248 |
The Baseline Analysis Population consists of All Treated Participants. Two participants in each treatment group did not receive study drug.
| Age, Customized(Participants) | Aprepitant Regimen | Control Regimen | Total |
|---|---|---|---|
| 20 to 29 years | 4 | 3 | 7 |
| 30 to 39 years | 5 | 10 | 15 |
| 40 to 49 years | 32 | 28 | 60 |
| 50 to 59 years | 73 | 65 | 138 |
| 60 to 69 years | 74 | 77 | 151 |
| ≥70 years | 54 | 65 | 119 |
| Sex: Female, Male(Participants) | Aprepitant Regimen | Control Regimen | Total |
|---|---|---|---|
| Female | 108 | 111 | 219 |
| Male | 134 | 137 | 271 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2012 to primary completion in Aug 2014, 19 months.
Results were first posted in Jul 2015, 11 months after primary completion.
Of 27 phase 4 interventional studies under Nausea, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 19 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aprepitant